Inger Johanne Zwicky Eide

Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study)

Inger Johanne Zwicky Eide, Åslaug Helland, Simon Ekman et al. · Lung Cancer · 2020 · 70 citations · Full text

Medicine, Oncology, Pharmacology +14

Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials

Inger Johanne Zwicky Eide, Simone Stensgaard, Åslaug Helland et al. · Translational Lung Cancer Research · 2022 · 23 citations · Full text

Medicine, Oncology, Pharmacology +13

Elevated expression of miR-494-3p is associated with resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer

Dominika Kaźmierczak, Inger Johanne Zwicky Eide, Radosveta Gencheva et al. · Translational Lung Cancer Research · 2022 · 20 citations · Full text

Medicine, Molecular Biology, Oncology +17

Ras-Related Protein Rab-32 and Thrombospondin 1 Confer Resistance to the EGFR Tyrosine Kinase Inhibitor Osimertinib by Activating Focal Adhesion Kinase in Non-Small Cell Lung Cancer

Zeinab Kosibaty, Odd Terje Brustugun, Inger Johanne Zwicky Eide et al. · Cancers · 2022 · 11 citations · Full text

Medicine, Oncology, Pharmacology +17

Epidemiology and outcome of peritoneal and pleural mesothelioma subtypes in Norway. A 20 year nation-wide study

Odd Terje Brustugun, Yngvar Nilssen, Inger Johanne Zwicky Eide · Acta Oncologica · 2021 · 10 citations · Full text

Medicine, Oncology, Pathology +14